The Effects of Cannabidiol (CBD) on Anorexia Nervosa: Safety and Tolerability Study (PI: Emily Gray, MD and Walter Kaye, MD)

This clinical trial will examine safety and tolerability and if and how cannabidiol (CBD), a chemical found in the cannabis plant, could potentially provide therapeutic benefits to adults with anorexia nervosa (AN). The trial is scheduled to launch in approximately one year.

Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa (AN) many individuals seek out alternative approaches to care. CBD is a major chemical compound found in cannabis. It does not produce the “high” caused by THC but interacts with the body’s endocannabinoid system; a network that regulates diverse physiological and cognitive processes including appetite, food intake, energy balance and anxiety.

The goals of the study are to determine: 1) if CBD is safe and tolerable and 2) whether it helps with the symptoms of AN including anxiety.

The clinical trial will enroll 10 adults, ages 18 and above, with a confirmed diagnosis of AN. All subjects will be blinded and will randomly receive placebo and active CBD at several doses.

If you are interested in hearing more about this study, click here to join our interest list.

Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego | HNRP |